Overview

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

Status:
Completed
Trial end date:
2007-01-23
Target enrollment:
Participant gender:
Summary
The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic hepatitis has been well established.The evidence in HBeAg negative patients is limited. Limited sustained response was observed post-treatment following a one year treatment period. Whether these results can be applied to patients in Iran is uncertain. This study is therefore intended to further assess the efficacy profile after two years of open treatment in the adult Iranian population.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
ViiV Healthcare
Treatments:
Lamivudine